Viruses 2011, 3(10), 1800-1814; doi:10.3390/v3101800

Next-Generation Dengue Vaccines: Novel Strategies Currently Under Development

1 Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, 624 N. Broadway, Room 251, Baltimore, MD 21205, USA 2 Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 33 North Drive, Room 3W10A, Bethesda, MD 20892, USA
* Author to whom correspondence should be addressed.
Received: 16 August 2011; in revised form: 20 September 2011 / Accepted: 20 September 2011 / Published: 26 September 2011
(This article belongs to the Special Issue Recent Progress in Dengue Virus Research)
PDF Full-text Download PDF Full-Text [267 KB, uploaded 26 September 2011 18:00 CEST]
Abstract: Dengue has become the most important arboviral infection worldwide with more than 30 million cases of dengue fever estimated to occur each year. The need for a dengue vaccine is great and several live attenuated dengue candidate vaccines are proceeding through clinical evaluation. The need to induce a balanced immune response against all four DENV serotypes with a single vaccine has been a challenge for dengue vaccine developers. A live attenuated DENV chimeric vaccine produced by Sanofi Pasteur has recently entered Phase III evaluation in numerous dengue-endemic regions of the world. Viral interference between serotypes contained in live vaccines has required up to three doses of the vaccine be given over a 12-month period of time. For this reason, novel DENV candidate vaccines are being developed with the goal of achieving a protective immune response with an immunization schedule that can be given over the course of a few months. These next-generation candidates include DNA vaccines, recombinant adenovirus vectored vaccines, alphavirus replicons, and sub-unit protein vaccines. Several of these novel candidates will be discussed.
Keywords: Dengue vaccine; DNA vaccine; vectored-vaccine; sub-unit protein vaccine

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Durbin, A.P.; Whitehead, S.S. Next-Generation Dengue Vaccines: Novel Strategies Currently Under Development. Viruses 2011, 3, 1800-1814.

AMA Style

Durbin AP, Whitehead SS. Next-Generation Dengue Vaccines: Novel Strategies Currently Under Development. Viruses. 2011; 3(10):1800-1814.

Chicago/Turabian Style

Durbin, Anna P.; Whitehead, Stephen S. 2011. "Next-Generation Dengue Vaccines: Novel Strategies Currently Under Development." Viruses 3, no. 10: 1800-1814.

Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert